Chapin Davis Inc. Purchases 21,000 Shares of Dyadic International, Inc. (NASDAQ:DYAI)

Chapin Davis Inc. boosted its position in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 at the end of the most recent quarter.

Separately, Callan Capital LLC acquired a new stake in Dyadic International in the 1st quarter valued at about $45,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Price Performance

NASDAQ DYAI remained flat at $1.32 during trading on Friday. 52,486 shares of the company were exchanged, compared to its average volume of 57,198. The company has a market capitalization of $38.59 million, a price-to-earnings ratio of -4.71 and a beta of 0.73. The firm’s fifty day moving average is $1.53 and its 200-day moving average is $1.58. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.29. Dyadic International, Inc. has a 52-week low of $1.13 and a 52-week high of $2.67.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $1.00 million. During the same period in the previous year, the firm posted ($0.07) EPS. Analysts anticipate that Dyadic International, Inc. will post -0.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Monday, July 8th.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.